Lantern Pharma Secures FDA Clearance Of IND Application For Drug Candidate LP-184 In Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma has secured FDA clearance for its IND application for drug candidate LP-184 in solid tumors. The first-in-human Phase 1A trial is expected to launch this quarter, with completion anticipated by the first half of 2024.
June 12, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma has received FDA clearance for its IND application for LP-184, with the Phase 1A trial set to launch this quarter.
The FDA clearance of Lantern Pharma's IND application for LP-184 is a significant milestone for the company. This approval allows the company to proceed with the first-in-human Phase 1A trial, which is expected to launch this quarter. The positive regulatory development is likely to have a short-term positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100